Document:

EX-10.9

 Exhibit 10.9 

CONFIDENTIAL 
 Execution Copy 

SUBLICENSE AGREEMENT 

This SUBLICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of December 17, 2018 (the
“Effective Date”), by and between Dermavant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051, Switzerland
(“Sublicensor”) and Roivant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051, Switzerland (“Sublicensee”). Each
of Sublicensor and Sublicensee may be referred to in this Agreement individually as a “Party” and collectively as the “Parties.” 

WHEREAS, Sublicensee entered into a License Agreement with AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its
registered office at SE-151 85 Södertälje, Sweden and with offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”) effective as of
September 19, 2017 (the “Head License”), pursuant to which Sublicensee received an exclusive license from AstraZeneca to research, develop, manufacture and commercialize certain products for all diagnostic, prophylactic and
therapeutic uses in humans and animals; 
 WHEREAS, Sublicensee (a) transferred, conveyed and assigned all of its rights under the Head
License to Sublicensor, excluding, as of the Effective Date, as related to China, Hong Kong, Macau and Taiwan (“Greater China”) and the Republic of Korea and all territories thereof (“South Korea”, and together with
Greater China, the “Reserved Territory”), and (b) may at a future time transfer to Sublicensor all of its rights under the Head License as related to one or more of the countries or administrative districts in the Reserved
Territory, in each case, pursuant to an Assignment and Assumption Agreement effective as of the date hereof (the “Assignment Agreement”); 

WHEREAS, Sublicensee has previously transferred, conveyed and assigned all of its rights under the Head License as related to the Reserved
Territory to Roivant China Holdings Ltd. (as successor in interest to Sinovant Sciences Ltd., a Bermuda exempted limited company) (“SSL”), pursuant to a China and South Korea IP Purchase Agreement, dated February 14, 2018
(“Sinovant Agreement”); 
 WHEREAS, SSL and its subsidiary, Sinovant Sciences HK Limited (“SinoHK”),
entered that certain Intellectual Property License Agreement, dated March 16, 2018, pursuant to which SSL sublicensed to SinoHK, inter alia, its intellectual property rights under the Sinovant Agreement in the Reserved Territory; 

WHEREAS, pursuant to Section 2.2 of the Head License, Sublicensor has certain rights to sublicense its rights under the Head License to
Affiliates and other Third Parties; and 
 WHEREAS, Sublicensor desires to grant to Sublicensee, and Sublicensee desires to obtain, a
sublicense under the Head License to certain of Sublicensor’s rights thereunder in respect of the research, development, manufacture and commercialization of Licensed Compounds and Licensed Products that pertain to the treatment, prevention and
diagnosis of any and all human and animal diseases, disorders and conditions, other than the Retained Field (the “Sublicensed Field”), worldwide, excluding any country or administrative district in the Reserved Territory unless or

  
 - 1 - 

 
until Sublicensee transfers all of its rights under the Head License in such country or administrative district in the Reserved Territory to Sublicensor, as contemplated in Section 2 of the
Assignment Agreement (the “Territory”), in all cases on the terms of, and subject to the conditions set forth in, this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth below, the parties hereby agree as
follows: 
 ARTICLE I 

SUBLICENSE 
 1.1 Grant
to Sublicensee. Subject to the other Sections of this Article I, and the other terms and conditions of this Agreement and the Head License, Sublicensor hereby grants to Sublicensee, an exclusive (even as to Sublicensor and its Affiliates)
sublicense (or license) and right of reference under the AstraZeneca Patents and the AstraZeneca Know-How, Licensee Patents, Licensee Know-How and any Improvements and
Regulatory Documentation for Licensed Compounds and Licensed Products, to research, Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize (collectively, “Exploit”)
Licensed Compounds and Licensed Products, in each case, in the Sublicensed Field in the Territory. 
 1.2 Sublicenses. Sublicensee may
grant sublicenses (or further rights of reference) under the licenses and rights of reference granted in Sections 1.1 or 1.5, in the Sublicensed Field either to (a) its Affiliates, (b) Affiliates of Sublicensor, in each case
of (a) and (b) without the prior written consent of Sublicensor or (c) Third Parties, but, in the case of (c), only with the prior written consent of Sublicensor, not to be unreasonably withheld; provided that any sublicenses
granted hereunder shall be consistent with, and expressly subject to, the terms and conditions of this Agreement and the Head License (including the obligation to provide a copy of any sublicense agreement to AstraZeneca under the Head License).
Sublicensee shall provide Sublicensor with a copy of any sublicense agreement prior to or as soon as practicable following the entrance into any such sublicense, but in all cases within fourteen (14) days of its execution (provided that
Sublicensee may redact from such copy any confidential information contained therein that is not necessary to ascertain compliance with this Agreement). 

1.3 Retained Rights. Notwithstanding anything to the contrary in this Agreement and without limitation of any rights granted to, or
reserved by, Sublicensor pursuant to any other term or condition of this Agreement, Sublicensor hereby expressly retains, on behalf of itself and its Affiliates (and on behalf of its licensors, (sub)licensees (other than Sublicensee) and
contractors), all right, title and interest in and to the AstraZeneca Patents and the AstraZeneca Know-How, Licensee Patents, Licensee Know-How and any Improvements and
Regulatory Documentation and any trademarks, trade names, branding or logos specific to AstraZeneca, Sublicensor and any of their Affiliates (other than Sublicensee), and all other rights of Sublicensor in the Head License or intellectual property
rights of Sublicensor otherwise relating to the Licensed Compounds and Licensed Products that are not expressly being sublicensed to Sublicensee hereunder, in each case for any of the following purposes: 

  
 - 2 - 

 (a) to perform its and their obligations under this Agreement; and 

(b) to develop, obtain and maintain regulatory approvals for and to research, develop, make, have made, use, distribute, sell, offer for sale,
have sold, import, export and otherwise and commercialize any compound or product (including the Licensed Compounds or Licensed Products) in, or to otherwise exercise any of its or their rights under the Head License that are not being sublicensed
hereunder with respect to, the Retained Field (as defined below) in the Territory. 
 For clarity, Sublicensor shall have the exclusive right to practice
the licenses granted by AstraZeneca under the Head License and Exploit any Improvement for, or to otherwise exercise any of its rights under the Head License that are not being sublicensed hereunder with respect to, the treatment, prevention and
diagnosis of any and all human and animal dermatological diseases, disorders and conditions (the “Retained Field”) in the Territory. 

1.4 Grant to Sublicensor. Sublicensee hereby grants to Sublicensor a non-exclusive license and
right of reference, with the right to sublicense (including through multiple tiers), under any Regulatory Documentation of Sublicensee as reasonably necessary (a) to Exploit Licensed Compounds and Licensed Products in the Retained Field in the
Territory and (b) for the purposes of Sublicensor otherwise exercising its retained rights and performing its obligations in accordance with Section 1.3. 

1.5 Cross License Grant. Sublicensor hereby grants to Sublicensee a non-exclusive license under
the Sublicensor New IP and Sublicensor’s rights under the Joint New IP to Exploit Licensed Compounds and Licensed Products, in each case, in the Sublicensed Field in the Territory and (b) Sublicensee hereby grants to Sublicensor a non-exclusive license under the Sublicensee New IP and Sublicensee’s rights under the Joint New IP to Exploit Licensed Compounds and Licensed Products, in each case, in the Retained Field in the Territory. For
the avoidance of doubt, the foregoing rights are only sublicensable by Sublicensee in accordance with Section 1.2, above and, in all cases, any restrictions set forth in the Head License. 

1.6 Clarification. This Agreement and the rights and obligations of Sublicensor and Sublicensee under this Agreement are expressly
subject to the terms and conditions of the Head License, including, without limitation, the following Sections and Articles of the Head License: Sections 2.2, 2.3, 2.4 and Article 6. 

1.7 Negative Covenants. Sublicensee hereby covenants not to Exploit any Licensed Compounds or Licensed Products for use in the Retained
Field. 
 1.8 No Other Rights Granted. Except as expressly provided herein and without limiting the foregoing, neither Party grants to
the other Party any other right or license, including any rights or licenses to any Patent, Trademark or other intellectual property rights not otherwise expressly granted herein. 

  
 - 3 - 

 ARTICLE II 

DEVELOPMENT; COMMERCIALIZATION; SUPPLY 

2.1 Development and Commercialization Reports. Sublicensee shall work with Sublicensor as reasonably necessary and requested by
Sublicensor to complete the Development reports in Section 3.3.4 of the Head License and the Commercialization reports in accordance with Section 3.5.4 of the Head License and as otherwise requested by Sublicensor, and shall cooperate and
participate in any further discussions or meetings in accordance with the Head License or as otherwise as requested by Sublicensor or AstraZeneca. 

2.2 Development and Commercialization Responsibilities. 

(a) Sublicensee shall be solely responsible for, and shall bear the entire cost of performing or having performed, all Development of Licensed
Compounds and Licensed Products in the Sublicensed Field in the Territory, and all Commercialization of Licensed Products in the Sublicensed Field in the Territory, and the satisfaction of all regulatory requirements with respect thereto. As between
the Parties, and subject to the provisions of Article IV. Sublicensee shall assume responsibility for fulfilling the obligations set forth in Article 3 of the Head License for the Sublicensed Field in the Territory. 

(b) Notwithstanding the provisions of Section 2.2(a), neither Party shall file for Regulatory Approval or apply for
or seek to obtain any designation, priority, exclusivity, accelerated approval, priority review voucher or similar right (including any orphan drug, rare disease, pediatric disease, tropical disease or breakthrough therapy or similar designations)
with respect to any Licensed Compounds and Licensed Products in any country or jurisdiction in the Territory (the Party first seeking Regulatory Approval, the “Filing Party”), without providing prior written notice to the non-Filing Party. If requested in writing by the non-Filing Party within seven (7) Business Days of receipt of such notice from the Filing Party, the Parties shall
discuss the regulatory pathway for the Licensed Compounds and Licensed Products in the Territory, and the Parties shall agree whether or not the Filing Party will file for Regulatory Approval and which Party shall be responsible for listings in the
FDA’s Orange Book, and under similar or equivalent laws in other countries or jurisdictions in the Territory, seeking to obtain any designation, priority, exclusivity, accelerated approval, priority review voucher or similar right (including
any orphan drug, rare disease, pediatric disease, tropical disease or breakthrough therapy or similar designations), and for which Patents the Parties will file patent term extensions; provided, however, that in the event the Parties
are not able to agree to any of the foregoing within a period of thirty (30) days following the date of receipt of the initial notice provided to the non-Filing Party, Sublicensor shall make the final
determination in respect thereto; provided, such determination must be reasonable under the then-existing circumstances. Without limiting the foregoing, neither Party shall be required to provide legally privileged or commercially sensitive
information in connection with the foregoing items unless and until procedures reasonably acceptable to the Party making such disclosure are in place to protect such privilege or information exchange. 

2.3 Subcontracting. Sublicensee may subcontract with a Third Party to perform any or all of its obligations hereunder (including by
appointing one or more distributors); provided that no such permitted subcontracting shall relieve Sublicensee of any obligation hereunder (except to the extent satisfactorily performed by such subcontractor) or any liability and Sublicensee
shall be and remain fully responsible and liable therefor. Without limiting the foregoing, each such permitted subcontracting agreement shall be on the same terms and conditions as those set forth in

  
 - 4 - 

 
this Agreement and the Head License, to the extent applicable to the subcontracted obligation and Sublicensee shall cause any subcontractor(s) engaged by it to be bound by written obligations of
confidentiality and non-use of AstraZeneca’s Confidential Information, Sublicensor’s Proprietary Information, and invention assignments consistent with those contained in this Agreement and in
Article 5 and Article 10 of the Head License, as applicable. Sublicensee hereby waives any requirement that Sublicensor exhaust any right, power or remedy, or proceed against any subcontractor for any obligation or performance under this Agreement
prior to proceeding directly against Sublicensee. For the purposes of this Agreement, “Third Party” shall mean any Person that is not a Party or an Affiliate of a Party. 

2.4 Compliance; Cooperation. Sublicensee shall: (a) conduct, and shall cause its Affiliates and sublicensees to conduct, all
Exploitation activities with respect to Licensed Compounds and Licensed Products in the Sublicensed Field in the Territory in compliance with all Applicable Laws and industry guidance; and (b) not employ or engage any Person who has been
debarred or disqualified by any Regulatory Authority or, to its knowledge, is the subject of debarment or disqualification proceedings by any Regulatory Authority. Sublicensor shall maintain the global safety database pursuant to its own policy and
as necessary to comply with Applicable Laws governing adverse experiences in the Territory. The Parties or their Affiliates shall enter into a pharmacovigilance agreement at such time and to the extent necessary, as mutually agreed between the
Parties. In the event that Sublicensee or its Affiliates sublicense any of their respective rights under this Agreement to a Third Party for the development or commercialization of Licensed Products or Licensed Compounds in the Sublicensed Field,
then, on either Party’s request, the Parties will discuss in good faith the allocation of operational responsibility for the management of the global safety database to ensure that such management is performed in an efficient and equitable
manner (including a reasonable allocation of the costs thereof). Without limiting the foregoing, if requested by Sublicensor, Sublicensee will use reasonable efforts to cause its sublicensees to enter into a separate pharmacovigilance agreement
directly with Sublicensor, which shall be on substantially the same terms as the pharmacovigilance agreement between Sublicensor and Sublicensee, absent substantial justification for material variation. 

2.5 Affiliates. 
 (a) For
the purposes of this Agreement, “Affiliate” shall mean, (i) with respect to Sublicensor, (x) prior to an acquisition of Dermavant Sciences Ltd., a company organized under the laws of Bermuda and its subsidiaries
(“DSL”) by a Third Party (whether by merger, stock sale or other similar transaction), any of the wholly owned subsidiaries (whether direct or indirect) of DSL, or any other entity that is directly or indirectly controlled by DSL
and (y) on and after an acquisition of DSL by a Third Party, any other Person (other than Sublicensee and Sublicensee’s wholly owned subsidiaries (whether direct or indirect)) that directly or indirectly controls, is controlled by or is
under direct or indirect common control with, Sublicensor, and (ii) with respect to Sublicensee, any other Person (other than Sublicensor and Sublicensor’s wholly owned subsidiaries (whether direct or indirect)) that directly or indirectly
controls, is controlled by or is under direct or indirect common control with, Sublicensee, in each case wherein the term “control” (including, with correlative meaning, the terms “controlled by” and “under the common
control”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the entirety of the management and policies of such Person. 

  
 - 5 - 

 (b) To the extent that this Agreement imposes obligations on the Affiliates of a Party, such
Party agrees to cause its Affiliates to perform such obligations. Each Party may contract with one or more of its Affiliates to perform its obligations hereunder; provided that such Party shall remain liable hereunder for the performance of
all of its obligations hereunder. 
 (c) To the extent that the Head License imposes obligations on the “Affiliates” of
“Licensee”, each Party agrees to cause its Affiliates to perform such obligations. 
 (d) Notwithstanding anything to the contrary
in this Section 2.5, for the purposes of this Agreement, Sublicensee (and its Affiliates) and DSL and its subsidiaries (including Sublicensor) shall not be deemed “Affiliates” of each other Party. 

ARTICLE III 
 PAYMENTS

 3.1 Sublicense Fee. Within fifteen (15) days after the Effective Date, Sublicensee shall pay to Sublicensor (to an
account specified by Sublicensor) an amount equal to two hundred and fifty thousand U.S. dollars ($250,000). The Parties shall have the right to adjust the consideration as deemed necessary by an independent third party valuation firm for purposes
of determining fair market value of the rights and license granted to Sublicensee under this Agreement as of the date of transfer. In the event the consideration is adjusted pursuant to this Section 3.1, the Party that owes
a true-up payment to the other Party will make such payment (to an account specified by the receiving party) within thirty (30) days after the date of the independent valuation firm’s report. 

3.2 Regulatory Milestone Payments. Sublicensee shall notify Sublicensor in writing within fifteen (15) days after the achievement
of any of the milestone events set forth in Section 4.2.1 of the Head License with respect to the Sublicensed Field in the Territory, and Sublicensor shall notify Sublicensee within five (5) Business Days thereafter whether such milestone
event was previously achieved for purposes of the Head License. If such milestone event was not so previously achieved, then the Parties shall promptly meet and discuss in good faith the appropriate allocation of the milestone payment specified in
Section 4.2.1 of the Head License as between the Parties in order for Sublicensor to timely satisfy its milestone payment obligations to AstraZeneca. For the avoidance of doubt, Sublicensee shall pay to Sublicensor any amounts as mutually
agreed (or, if the parties cannot agree, as finally determined by an adjudicating authority) to be allocable to Sublicensee in respect of the achievement of the relevant milestone in Section 4.2.1 of the Head License as soon as reasonably
possible following the final allocation thereof. Notwithstanding anything to the contrary, the Parties shall use reasonable efforts to reach an agreement to make any such payments prior to the due date of the corresponding milestone payment to
AstraZeneca under the Head License. Nothing herein shall be construed to prevent or hinder Sublicensor’s right to make any payments required pursuant to Section 4.2.1 of the Head License, including making such payments prior to any
agreement or final determination of the appropriate allocation of such amounts as between the Parties. 

  
 - 6 - 

 3.3 First Commercial Sale, Commercial Milestones, Royalty Term and Royalty Reductions,
Reports and Payment. 
 (a) Each Party shall promptly notify the other Party of the date of the First Commercial Sale made by such Party
or its Affiliates or sublicensees for each Licensed Product in each country or jurisdiction in the Territory. 
 (a) Within fifteen
(15) days after the end of each Calendar Quarter after First Commercial sale by Sublicensee or its Affiliates or sublicensees of a Licensed Product in the Sublicensed Field in the Territory, Sublicensee shall deliver to Sublicensor a statement
(a “Net Sales Report”) specifying, on a Licensed Product-by-Licensed Product and
country-by-country basis, (i) the amount of Invoiced Sales, (ii) Net Sales and deductions taken to arrive at Net Sales attributable to each Licensed Product in
each country the Territory during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars), and (iii) a calculation of the amount of royalty payment due on such Net Sales for such Calendar
Quarter, if any, pursuant to Section 4.3 of the Head License. 
 (b) Within ten (10) days after receipt by Sublicensor of each Net
Sales Report, Sublicensor shall provide Sublicensee with a report (a “Royalty Payment Report”) stating the actual amount of royalties payable by Sublicensee on Net Sales of Licensed Product in the Sublicensed Field in the Territory,
as calculated on a pro rata basis between the Parties and their respective Affiliates based on the respective Net Sales of each Party’s and its Affiliates’ Licensed Products sold during the applicable Calendar Quarter, taking into
account the pro rata amount of any royalty adjustments, as set forth in Section 4.3 of the Head License, which pertain to Sublicensee’s sale of Licensed Products in the Sublicensed Field in the Territory. Sublicensor shall maintain
complete and accurate records in sufficient detail to permit Sublicensee to confirm the accuracy of each Royalty Payment Report. Sublicensor agrees to make such records available to Sublicensee upon Sublicensee’s reasonable request and to
cooperate to answer any related queries of Sublicensee. If Sublicensee disputes the accuracy of any Royalty Payment Report, the Parties shall work in good faith to resolve the disagreement. 

(c) Within fifteen (15) days after receipt by Sublicensee of each Royalty Payment Report, Sublicensee shall pay to Sublicensor, in
accordance with Section 4.4, the amount of royalties owed by Sublicensee as set forth in the applicable Royalty Payment Report. 

(d) The calculation of all commercial milestones payable to AstraZeneca under Section 4.2.2 of the Head License shall
be made on a pro rata basis between the Parties and their respective Affiliates based on the respective Net Sales of each Party’s and their Affiliates’ Licensed Products sold in the applicable period resulting the achievement of
such commercial milestone. 
 3.4 Mode of Payment; Offsets. All payments to Sublicensor under this Agreement shall be made by deposit
of Dollars in the requisite amount to such bank account as Sublicensor may from time to time designate by notice to Sublicensee. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the
calculation of Net Sales expressed in currencies other than Dollars), the Parties shall convert any amount expressed in a foreign currency into Dollar equivalents using such Party’s, its Affiliate’s or sublicensee’s, as applicable,
standard conversion methodology consistent with GAAP. Sublicensee shall have no right to offset, set off or deduct any amounts from or against the amounts due to Sublicensor hereunder. 

  
 - 7 - 

 3.5 Third Party License. 

(a) If in the reasonable opinion of Sublicensee, the Exploitation of Licensed Compounds or Licensed Products in the Sublicensed Field in the
Territory by Sublicensee or any of its Affiliates infringes or is reasonably expected to infringe any Patent of a Third Party in any country in the Territory (such right, a “Third Party Patent Right”), then Sublicensee shall inform
Sublicensor and shall promptly provide Sublicensor with the Patents in question. Sublicensor shall determine, in its sole opinion, whether the Third Party Patent Rights are necessary for the Exploitation of either Licensed Compounds or a Licensed
Product in the Retained Field or the Sublicensed Field. Without limiting the foregoing, on either Party’s request, prior to any discussions regarding such Third Party Patent Rights, the Parties shall enter into an agreement to provide
protections for any legally privileged or commercially sensitive information intended to be exchanges in connection with the foregoing. 

(b) If Sublicensor determines that the Third Party Patent Rights are necessary for the Exploitation of Licensed Compounds or a Licensed Product
in either the Retained Field or the Sublicensed Field (or both) then, as between the Parties, Sublicensor shall have the right, but not the obligation, to negotiate and obtain a license from such Third Party to such Third Party Patent Right as
necessary or desirable for (i) Sublicensor or its Affiliates or its or their sublicensees to Exploit Licensed Compounds and Licensed Products in the Retained Field in such country and/or (ii) Sublicensee or its Affiliates to Exploit
Licensed Compounds and Licensed Products in the Sublicensed Field in such country. Sublicensor may elect, at its sole option, to require Sublicensee, and Sublicensee hereby agrees to, reimburse Sublicensor or its Affiliates for, a portion (or all)
of the costs and expenses (including reasonable attorneys’ fees) incurred in connection therewith, including any royalties, milestones or other payments incurred under any such license. Upon execution by Sublicensor of any such license for
Third Party Patent Rights, such Third Party Patent Rights shall be deemed included in the licenses granted to Sublicensee pursuant to Section 1.1 and 1.5. 

(c) In the event Sublicensor elects, for any reason, not to obtain a license from a Third Party to Third Party Patent Rights in accordance with
Section 3.5(b), Sublicensee shall, upon the written consent of Sublicensor, have the right, but not the obligation, to do so, provided that such license is limited to the rights necessary or desirable for Sublicensee
or its Affiliates to Exploit Licensed Compounds or Licensed Products in the Sublicensed Field in the applicable country in the Territory. Sublicensee shall bear all expenses incurred in connection therewith, including any royalties, milestones or
other payments incurred under any such license. In the event that Sublicensee obtains a license from a Third Party to Third Party Patent Rights in accordance with this Section 3.5(c) and Sublicensor desires a sublicense to
such rights, Sublicensee shall grant to Sublicensor a non-exclusive license, including the right to sublicense (through multiple tiers) under the Third Party Patent Rights to Exploit Licensed Compounds and
Licensed Products in the Retained Field in the Territory, and Sublicensor shall pay such amounts as agreed between the Parties for such sublicense. 

(d) Either Party’s right to seek a license to any Third Party Patent Rights shall be expressly subject to the obligations and rights of
AstraZeneca, as set forth in additional detail in Section 5.6 of the Head License. 

  
 - 8 - 

 ARTICLE IV 

INTELLECTUAL PROPERTY 

4.1 Patent Maintenance and Prosecution. 

(a) Prosecution. For purposes of this Section 4.1, the Party prosecuting, maintaining or undertaking other related
activities pursuant to this Agreement with respect to a Patent shall be the “Prosecuting Party.” As between the Parties, (a) Sublicensor shall have the right, but not the obligation, to prepare, file, prosecute and maintain the
AstraZeneca Patents, the Licensee Patents and any Patents contained in, or otherwise relating to, any Sublicensor New IP or Joint New IP, and (b) Sublicensee shall have the right, but not the obligation, to prepare, file, prosecute and maintain
any Patents contained in, or otherwise relating to, any Sublicensee New IP, (the Patents in clause (a) and (b), as applicable, the “Subject Patents”), in each case, in both the Retained Field and the Sublicensed Field, in the
Territory, at the Prosecuting Party’s sole cost and expense. Before each submission is filed, the Prosecuting Party shall provide the non-Prosecuting Party with the opportunity to review and comment on
proposed, substantive submissions to any patent office at least ten (10) days prior to its intended submission. The non-Prosecuting Party shall, and shall cause its Affiliates to, assist and cooperate
with the Prosecuting Party, as the Prosecuting Party may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the Subject Patents in the Territory under this Agreement, including that the non-Prosecuting Party shall, and shall ensure that its Affiliates, (i) offer its comments, if any, promptly, (ii) provide access to relevant documents and other evidence and make its employees available at
reasonable business hours; provided, however, that neither Party shall be required to provide legally privileged information with respect to such intellectual property unless and until procedures reasonably acceptable to such Party are in
place to protect such privilege; and provided, further, that the Prosecuting Party shall reimburse the non-Prosecuting Party for its reasonable and verifiable costs and expenses incurred in connection
therewith. 
 (b) Step-In Rights. In the event that the Prosecuting Party desires to abandon
or cease prosecution or maintenance of any Subject Patent, the Prosecuting Party shall provide reasonable prior written notice to the non-Prosecuting Party of such intention to abandon (which notice shall, to
the extent possible, be given no later than thirty (30) days prior to the next deadline for any action that must be taken with respect to any such Patent in the relevant patent office). In such case, upon the
non-Prosecuting Party’s written election provided no later than fifteen (15) days after such notice from the Prosecuting Party, the non-Prosecuting Party shall
have the right to assume prosecution and maintenance of such Patent at the non-Prosecuting Party’s expense. If the non-Prosecuting Party does not provide such
election within fifteen (15) days after such notice from the Prosecuting Party, the Prosecuting Party may, in its sole discretion, continue prosecution and maintenance of such Patent or discontinue prosecution and maintenance of such Patent.

 4.2 Patent Enforcement. 

(a) Notice. Each Party shall promptly notify the other Party in writing of (i) any alleged or threatened infringement of the
Subject Patents in any jurisdiction in the Territory or (ii) any certification filed under the Hatch-Waxman Act claiming that any Subject Patents are invalid or unenforceable or claiming that any Subject Patents would not be infringed by the
making, use, offer for sale, sale or import of a product for which an application under the Hatch-Waxman Act is filed or any equivalent or similar certification or notice in any other jurisdiction, in each case ((i) and (ii)) of which such Party
becomes aware (an “Infringement”). 

  
 - 9 - 

 (b) Enforcement of Patents. For purposes of this
Section 4.2, the Party prosecuting any Infringement with respect to a Subject Patent shall be the “Enforcing Party”. As between the Parties, (i) Sublicensor shall have the right, but not the
obligation, to prosecute any Infringement with respect to the AstraZeneca Patents, the Licensee Patents and any Patents contained in, or otherwise relating to, any Sublicensor New IP or Joint New IP, and (ii) Sublicensee shall have the right,
but not the obligation, to prosecute any Infringement with respect to any Patents contained in, or otherwise relating to, any Sublicensee New IP, each, including as a defense or counterclaim in connection with any Third Party Infringement, in both
the Retained Field and the Sublicensed Field, in the Territory, at the Enforcing Party’s sole cost and expense. In the event the Enforcing Party prosecutes any such Infringement in the Territory, the
non-Enforcing Party may, in the sole discretion of the Enforcing Party, be permitted to join as a party to such claim, suit or proceeding and participate with its own counsel at its sole cost and expense;
provided that the Enforcing Party shall retain control of the prosecution of such claim, suit or proceeding, including the response to any defense or defense of any counterclaim raised in connection therewith. 

(c) Step-In Rights. If the Enforcing Party fails to bring an action or proceeding with respect
to such Infringement of any Subject Patent within (1) thirty (30) days following the notice of alleged infringement or declaratory judgment or (2) fifteen (15) days before the time limit, if any, set forth in the appropriate laws and
regulations for the filing of such actions, whichever comes first, the non-Enforcing Party shall have the right, but not the obligation, to bring and control any such action at its own expense and by counsel
of its own choice, and the Enforcing Party shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(d) Cooperation. The Parties agree to cooperate fully in any Infringement action pursuant to this Section 4.2, including by
making the inventors, applicable records and documents (including laboratory notebooks) with respect to the relevant Patents available to the Enforcing Party on the Enforcing Party’s request. The
non-Enforcing Party shall, and shall cause its Affiliates to, assist and cooperate with the Enforcing Party, as the Enforcing Party may reasonably request from time to time, in connection with its activities
set forth in this Section, including where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its
employees available at reasonable business hours; provided that, the Enforcing Party shall reimburse the non-Enforcing Party for its reasonable and verifiable costs and expenses incurred in connection
therewith. Unless otherwise set forth herein, the Enforcing Party shall have the right to settle such claim. 
 (e) Recovery. Except
as otherwise agreed by the Parties in connection with a cost sharing arrangement, any recovery realized as a result of such litigation described above in this Section 4.2 (whether by way of settlement or otherwise) shall be
(i) first, allocated to pay to AstraZeneca any amounts owed to it pursuant to Section 5.3.4 of the Head License, (ii) second, allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall
be allocated pro rata if insufficient to cover the totality of such expenses), and (iii) third, paid to (or retained by) the Enforcing Party. 

  
 - 10 - 

 4.3 Infringement Claims by Third Parties. For purposes of this
Section 4.3, the Party defending any Third Party Infringement Claim shall be the “Defending Party”. If the Exploitation of a Licensed Product by Sublicensor, Sublicensee or any of their Affiliates or
sublicensees, results in, or is reasonably expected to result in, any claim, suit or proceeding by a Third Party alleging infringement by Sublicensee or any of its Affiliates or its or their sublicensees (a “Third Party Infringement
Claim”), excluding any defense or counterclaim in connection with an Infringement action initiated pursuant to Section 4.2, the Party first becoming aware of such alleged infringement shall promptly notify the
other Party thereof in writing. As between the Parties, (a) Sublicensor shall have the right, but not the obligation, to defend any such claim, suit or proceeding with respect to the AstraZeneca Patents, the Licensee Patents and any Patents
contained in, or otherwise relating to, any Sublicensor New IP or Joint New IP, and (b) Sublicensee shall have the right, but not the obligation, to defend any such claim, suit or proceeding with respect to any Patents contained in, or
otherwise relating to, any Sublicensee New IP, in each case, in both the Retained Field and the Sublicensed Field, in the Territory, at the Defending Party’s sole cost, using counsel of the Defending Party’s choice. The non-Defending Party shall, and shall cause its Affiliates to, assist and cooperate with the Defending Party, as the Defending Party may reasonably request from time to time, in connection with its activities set
forth in this Section, including where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its
employees available at reasonable business hours; provided that the Defending Party shall reimburse the non-Defending Party for its reasonable and verifiable costs and expenses incurred in connection
therewith. The Defending Party shall keep the non-Defending Party reasonably informed of all material developments in connection with any such claim, suit or proceeding. The Defending Party agrees to provide
the non-Defending Party with copies of all material pleadings filed in such action and to allow the non-Defending Party reasonable opportunity to participate in the
defense of the claims. Any damages, or awards, including royalties incurred or awarded in connection with any Third Party Infringement Claim defended under this Section 4.3 shall be borne by the Defending Party. In the
event that the Defending Party elects not to defend against such Third Party Infringement Claims within sixty (60) days of learning of same, the non-Defending Party shall have the right, but not the
obligation, to defend against such an action, subject in all cases to the assistance and cooperation provisions of this Section 4.3. 

4.4 Invalidity or Unenforceability Defenses or Actions. Each Party shall promptly notify the other Party in writing of any alleged, or
threatened, or actual assertion of invalidity or unenforceability of any of the Subject Patents by a Third Party, including, without limitation, in connection with any inter partes review, post grant review, reexamination and other similar
proceeding before the relevant patent office, a declaratory judgement action of invalidity, a revocation action and other similar proceeding filed in any court or similar tribunal in the Territory (collectively, an “Invalidity
Claim”), and of which such Party becomes aware. For purposes of this Section 4.4, the Party defending the Invalidity Claim with respect to a Patent shall be the “Controlling Party.” As between the
Parties, (a) Sublicensor shall have the right, but not the obligation, to defend and control the defense of an Invalidity Claim with respect to the AstraZeneca Patents, the Licensee Patents and any Patents contained in, or otherwise relating
to, any Sublicensor 

  
 - 11 - 

 
New IP or Joint New IP, and (b) Sublicensee shall have the right, but not the obligation, to defend and control the defense of an Invalidity Claim with respect to any Patents contained in,
or otherwise relating to, any Sublicensee New IP, each, including when such Invalidity Claim is raised as a defense or counterclaim in connection with an Infringement action initiated pursuant to Section 4.2, in both the Retained Field
and the Sublicensed Field, in the Territory, at the Controlling Party’s sole cost and expense. The non-Controlling Party shall, and shall cause its Affiliates to, assist and cooperate with the Controlling
Party, as the Controlling Party may reasonably request from time to time in connection with its activities set forth in this Section 4.4, including where necessary, furnishing a power of attorney solely for such purpose or joining in, or
being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours; provided that the Controlling Party shall reimburse the non-Controlling Party for its reasonable and verifiable costs and expenses incurred in connection therewith. In the event that the Controlling Party elects not to defend against such Invalidity Claims within sixty
(60) days of learning of same, the non-Controlling Party shall have the right, but not the obligation, to defend against such an action, subject in all cases to the assistance and cooperation provisions
of this Section 4.4. In addition, each Controlling Party shall ensure that it complies with Section 5.5 of the Head License in relation to any action described in this Section 4.4 that related to the AstraZeneca Patents and any
information, consultation and comment rights AstraZeneca has thereunder. 
 4.5 New Intellectual Property. 

(a) New IP. Subject to the rights and obligations of the Parties pursuant to Sections 1.1, 1.4 and this Article IV,
as between the Parties, each Party shall solely own any Inventions created or made under, pursuant to, or in connection with this Agreement solely by its or its Affiliates’ employees agents or independent contractors and the Parties shall
jointly own any Inventions that are made jointly by one or more employees, agents or independent contractors of one Party or its Affiliates and one or more employees, agents or independent contractors of the other Party or its Affiliates
(collectively, “New IP”). For the purposes of this Agreement, (i) “Sublicensor New IP” shall mean any New IP generated solely by Sublicensor, (ii) “Sublicensee New IP” shall mean any New IP
generated solely by Sublicensee and (iii) “Joint New IP” shall mean any New IP generated jointly by the Parties. 
 (b)
Disclosure. Each Party shall promptly disclose to the other Party any New IP generated by such Party under this Agreement. 
 4.6
Joint Interest Agreement. The Parties understand and agree that certain matters exchanged under this Agreement may be sensitive or privileged and, if either Party deems it reasonably advisable, on the request of such Party, the Parties will
enter into a mutually agreeable common interest agreement covering the matters contemplated by this Agreement and any communications or disclosures made hereunder. 

  
 - 12 - 

 ARTICLE V 

FURTHER ASSURANCES AND COVENANTS 

5.1 Head License Performance. Each Party covenants to the other Party that it will perform, satisfy and discharge all of
Sublicensor’s obligations pursuant to the Head License in accordance with the applicable terms of the Head License; provided that this Section 5.1 shall only apply to Sublicensee to the extent such obligations
are expressly sublicensed to Sublicensee pursuant to this Agreement. 
 5.2 Allocation of Responsibility under Head License. Unless a
right or obligation of Sublicensor under the Head License is expressly sublicensed to Sublicensee pursuant to this Agreement, such right or obligation shall remain the right or obligation of Sublicensor. 

5.3 Covenants Regarding Head License. 

5.3.1 Sublicensor has provided to Sublicensee in writing prior to the Effective Date a true, correct, and complete copy of the Head License,
and such copy includes any and all amendments, restatements, side letters, and other modifications thereto, as such Head License is in effect as of the Effective Date; 

5.3.2 Neither Sublicensor nor any Affiliate has received any written communication from AstraZeneca or any of its affiliates as of the
Effective Date related to any threatened or potential termination of the Head License; and 
 5.3.3 Sublicensor hereby agrees that
(a) Sublicensee shall have the right, but not the obligation, to cure any claimed default or breach by Sublicensor under the Head License that is solely with respect to the Sublicensed Field in the Territory that could reasonably likely result
in the termination of the Head License by AstraZeneca, (b) Sublicensor shall promptly notify Sublicensee of any such claimed default or breach and (c) Sublicensor shall reimburse Sublicensee for its costs and expenses associated therewith.

 ARTICLE VI 

REPRESENTATIONS, WARRANTIES, AND INDEMNITIES 

6.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party, as of the Effective Date, as
follows: 
 (a) Duly Organized. Each Party (i) is a corporation or limited liability company, with restricted liability, duly
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization and (ii) is qualified to do business and is in good standing as a foreign corporation or organization in each jurisdiction
in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such qualification would prevent such Party from performing its obligations under this Agreement. 

  
 - 13 - 

 (b) Due Authorization; Binding Agreement. The execution, delivery and performance of
this Agreement by such Party have been duly authorized by all necessary corporate or organizational action. This Agreement is a legal and valid obligation binding on such Party and enforceable in accordance with its terms subject to the effects of
bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is
considered in the proceeding at law or equity. The execution, delivery and performance of this Agreement by such Party does not: (i) violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court,
governmental body or administrative or other agency having jurisdiction over such Party; or (ii) conflict with, or constitute a default under, any agreement, instrument or understanding a court or administrative order, oral or written, to which
such Party is a party or by which it is bound. 
 (c) No Conflicting Grant of Rights. Such Party has the right to grant (or cause its
Affiliates to grant) the rights granted by such Party to the other Party under this Agreement and has not granted any rights to any Person that are in conflict with the rights granted by such Party to the other Party under this Agreement. 

6.2 Indemnity. 
 (a)
Sublicensee shall indemnify, defend and hold Sublicensor and its Affiliates, and their respective directors, officers, employees and agents (the “Sublicensor Indemnitees”), harmless from and against all liabilities, damages,
expenses and/or losses, including reasonable legal expenses and attorneys’ fees, and any other expenses of any nature, (“Losses”) resulting directly from any claim of damages (including those arising from any claims of
intellectual property infringement), bodily injury, death or property damage made by any Third Party (which, for the avoidance of doubt, shall include AstraZeneca) (such claim, a “Third Party Claim”) resulting from (i) the use,
Development, manufacture, Commercialization, handling, storage or other disposition by or on behalf of Sublicensee or any of its Affiliates or sublicensees of any Licensed Compound or Licensed Product in the Sublicensed Field in the Territory,
including any product liability claim; (ii) the negligence or willful misconduct of any of the Sublicensee Indemnitees under this Agreement; (iii) the material breach by Sublicensee of any of the covenants, warranties or representations
made by Sublicensee pursuant to this Agreement; or (iv) any material breach by Sublicensee of its obligations pursuant to this Agreement, except in each case to the extent due to the negligence or willful misconduct of Sublicensor or its Affiliates
or the breach by Sublicensor of any warranty, representation or obligation of Sublicensor under this Agreement or the Head License. 
 (b)
Sublicensor shall indemnify, defend and hold Sublicensee and its Affiliates, and their respective directors, officers, employees and agents (the “Sublicensee Indemnitees”), harmless from and against all Losses resulting directly
from any Third Party Claim resulting from (i) the use, Development, manufacture, Commercialization, handling, storage or other disposition by or on behalf of Sublicensor or any of its Affiliates or sublicensees (excluding Sublicensee) of any
Licensed Compound or Licensed Product in the Retained Field in the Territory, including any product liability claim; (ii) the negligence or willful misconduct of any of the Sublicensor Indemnitees under this Agreement; (iii) the material
breach by Sublicensor of any of the covenants, warranties or representations made by Sublicensor pursuant to this 

  
 - 14 - 

 
Agreement; or (iv) any material breach by Sublicensor of its obligations pursuant to this Agreement, except in each case to the extent due to the negligence or willful misconduct of
Sublicensee or its Affiliates or the breach by Sublicensee of any warranty, representation or obligation of Sublicensee under this Agreement. 

(c) If a Party (the “Indemnitee”) intends to claim indemnification under this
Section 6.2, it shall promptly notify the other Party (the “Indemnitor”) in writing of any Third Party Claim for which the Indemnitee intends to claim such indemnification. The
failure of the Indemnitee to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action shall relieve the Indemnitor of any obligation to the Indemnitee under this
Section 6.2 with respect to any such action, insofar as the failure prejudices the Indemnitor’s ability to defend such Third Party Claim. The Indemnitee shall permit the Indemnitor to control the litigation and/or
settlement of such Third Party Claim, and shall cooperate fully with Indemnitor in all matters related thereto, provided that unless agreed by the Indemnitee (i) counsel appointed by the Indemnitor to defend the Indemnitee shall not take
any position that if sustained would cause the Indemnitee not to be indemnified by the Indemnitor and (ii) no settlement shall involve any terms binding on the Indemnitee except payment of money to be paid by the Indemnitor. If the Indemnitor does
not so assume control of the defense of such Third Party Claim, the Indemnitee may conduct such defense with counsel of the Indemnitee’s choice but may not settle such case without the written consent of the Indemnitor, such consent not to be
unreasonably withheld or delayed. In addition, the Indemnitor shall have the right to assume control of the defense, at its own expense, at any time upon five (5) days’ prior notice to the Indemnitee. If the Indemnitor is controlling the
defense of a Third Party Claim, the Indemnitee may participate in such defense with the Indemnitee’s own counsel, reasonably acceptable to the Indemnitor, who shall be retained at the Indemnitee’s sole cost and expense. Notwithstanding the
foregoing, Sublicensor shall have the right, but not the obligation, to control any Third Party Claim brought against either Party by AstraZeneca alleging any Loss under the Head License. 

ARTICLE VII 
 GOVERNING
LAW AND DISPUTE RESOLUTION 
 7.1 Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of
the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the
application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods. 
 7.2 Arbitration.

 (a) The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or
related to this Agreement or the breach thereof. Subject to Section 7.3, in the event the Parties cannot resolve such dispute, controversy or claim within a period of thirty (30) days, then the matter shall be referred to designated
senior executives of the Parties for resolution. The initial designated senior executive for each Party shall be its chief business offer (or comparable position). Each Party shall be entitled to name substitute senior executives upon written notice
to the other Party. 

  
 - 15 - 

 (b) Except as expressly set forth in Section 7.3, if, after going through this
procedure, the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an Excluded Claim (as defined below) shall be finally resolved by binding arbitration administered by JAMS
pursuant to JAMS’ Streamlined Arbitration Rules and Procedures then in effect (the “JAMS Rules”). 
 (c) The
arbitration shall be conducted by a panel of three (3) neutral arbitrators experienced in the pharmaceutical business, none of whom shall be a current or former employee or director, or a current stockholder, of either Party or any of their
respective Affiliates or any sublicensee thereof: within thirty (30) days after initiation of arbitration, each Party shall select one (1) person to act as arbitrator and the two (2) Party-selected arbitrators shall select a third
(3rd) arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third (3rd) arbitrator, the third (3rd) arbitrator shall be appointed by JAMS. The place of
arbitration shall be New York, New York, and all proceedings and communications shall be in English. Within thirty (30) days after selection of the third arbitrator, the arbitrators shall conduct the Preliminary Conference (as defined in the
JAMS Rules). In addressing any of the subjects within the scope of the Preliminary Conference, the arbitrators shall take into account both the desirability of making discovery efficient and cost-effective and the needs of the Parties for an
understanding of any legitimate issue raised in the arbitration. The award rendered by the arbitrators shall be final, binding and non-appealable, and judgment may be entered upon it in any court of competent
jurisdiction. 
 (d) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the
controversy is otherwise resolved. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration. 

(e) Except to the extent necessary to confirm or enforce an award or as may be required by law, neither Party nor an arbitrator may disclose
the existence, content, or results of an arbitration without the prior written consent of the other Party. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute,
controversy or claim would be barred by the applicable New York statute of limitations. 
 (f) The Parties agree that, in the event of a
dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. The Parties further agree that any payments
made pursuant to this Agreement pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due. 

(g) As used in this Section, the term “Excluded Claim” means a dispute, controversy or claim that concerns (i) the
construction, scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or copyright; or (ii) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

  
 - 16 - 

 7.3 Equitable Relief. 

(a) Notwithstanding Section 7.2, to the fullest extent provided by Applicable Law, either Party may bring an action in any state or
federal court of competent jurisdiction in the County of New York, State of New York for preliminary or permanent injunctive relief, or seeking any provisional remedy, to protect a Party’s rights or enforce a Party’s obligations under this
Agreement pending final resolution of any claims related thereto pursuant to the dispute resolution procedure set forth in Section 7.2. 

(b) In addition, notwithstanding Section 7.2, each Party shall have the right to bring an action in any state or
federal court of competent jurisdiction to seek specific performance of the other Party’s obligations under this Agreement. 
 7.4
Jurisdiction. Subject to Sections 7.2 and 7.3, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of the County of New York, State of New York for any action, suit or
proceeding (other than appeals therefrom) arising out of or relating to this Agreement and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties irrevocably and
unconditionally waive their right to a jury trial. 
 7.5 Venue. The Parties further hereby irrevocably and unconditionally waive any
objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of New York and hereby further irrevocably and unconditionally waive and agree not to plead
or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 

7.6 Service. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set
forth in Section 10.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

ARTICLE VIII 
 TERM AND
TERMINATION 
 8.1 Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in
accordance herewith, shall continue in force and effect until the date of expiration or termination of the Head License with respect to any Licensed Product in the Sublicensed Field in the Territory (such period, the “Term”). For
the avoidance of doubt, the expiration of the Royalty Term with respect to a Licensed Product in the Sublicensed Field in any country in the Territory shall not be deemed an expiration or termination of the Head License unless such expiration of the
Royalty Term results in the reversion to AstraZeneca of the right to Exploit the applicable Licensed Product. 

  
 - 17 - 

 8.2 Termination. 

(a) Material Breach. In the event that Sublicensee is in material breach of its obligations under this Agreement, in addition to any
other right and remedy Sublicensor may have, Sublicensor may terminate this Agreement by providing sixty (60) days (the “Notice Period”) prior written notice to Sublicensee specifying the breach and its claim of right to
terminate; provided that the termination shall not become effective at the end of the Notice Period if Sublicensee cures the breach specified in the foregoing notice during the Notice Period. 

(b) Termination for Convenience. Sublicensee shall have right to terminate this Agreement in its entirety without cause, upon sixty
(60) days prior written notice to Sublicensor. 
 (c) Effects of Termination. In the event of the termination of this Agreement
for any reason: 
 (i) all rights and license granted by Sublicensor to Sublicensee hereunder shall immediately terminate; 

(ii) Sublicensee shall and hereby does, and shall cause its Affiliates to, assign to Sublicensor or its designee all of its right, title and
interest in and to (A) each (I) Licensee Patent, (II) trademark, (III) license to any Third Party Patent Rights, (IV) agreement with a subcontractor, and (V) any other property or assets, in each case primarily related to a
Licensed Compound or Licensed Product in the Sublicensed Field in the Territory and (B) all Regulatory Documentation applicable to any Licensed Compounds or Licensed Products then owned or Controlled by Sublicensee or any of its Affiliates;
provided, that if any such Regulatory Documentation is not immediately transferable in a country, Sublicensee shall provide Sublicensor with all benefit of such Regulatory Documentation, as applicable, and such assistance and cooperation as
necessary or reasonably requested by Sublicensor to timely transfer such Regulatory Documentation, as applicable, to Sublicensor or its designee or, at Sublicensor’s option, to enable Sublicensor to obtain a substitute for such Regulatory
Documentation, as applicable, without disruption to Sublicensor’s Exploitation of Licensed Compound(s) or applicable Licensed Product(s); and 

(iii) Sublicensee shall and hereby does, and shall cause its Affiliates to, effective as of the effective date of termination, grant
Sublicensor a non-exclusive, royalty-free license and right of reference, with the right to grant multiple tiers of sublicenses and further rights of reference, in and to all Regulatory Documentation
(including, for clarity any Drug Approval Application or Regulatory Approvals) then owned or Controlled by Sublicensee or any of its Affiliates that are not assigned to Sublicensor or is designees pursuant to clause (ii) above to Exploit in the
Territory any Licensed Compound or Licensed Product. 
 8.3 Accrued Rights; Surviving Obligations. Termination of this Agreement for
any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination. Such termination shall not relieve a Party from obligations that are expressly indicated to survive the termination of
this Agreement. Without limiting the foregoing, Section 6.2, and this Section 8.3 and Articles VII, IX and X of this Agreement shall survive the termination of this Agreement for any reason. 

  
 - 18 - 

 ARTICLE IX 

CONFIDENTIALITY 
 9.1
Definition of Proprietary Information. Proprietary Information of a Party means all means any technical, business or other information provided by or on behalf of one Party to the other Party in connection with this Agreement, The terms of
this Agreement are the Proprietary Information of both Parties and any information that would be ‘Confidential Information’ (as defined in the Head License), shall likewise be Proprietary Information under this Agreement. 

9.2 Non-use and non-disclosure. All Proprietary
Information disclosed by a Party (the “Discloser”) or its Affiliates under this Agreement will be maintained in confidence and otherwise safeguarded by the recipient Party (the “Recipient”) and its Affiliates using
at least the same standard of care as the Recipient uses to protect its own proprietary or Proprietary Information (but in no event less than reasonable care). In addition, the Recipient may (a) only use any such Proprietary Information for the
purposes of performing its obligations or exercising its rights under this Agreement or the Head License, as applicable; and (b) only disclose Proprietary Information of the Discloser to: (i) the Recipient’s Affiliates and
sublicensees; and (ii) employees, directors, agents, contractors, consultants and advisers of the Recipient and its Affiliates and sublicensees, in each case to the extent reasonably necessary for the purposes of, and for those matters
undertaken pursuant to, this Agreement; provided, that such Persons are bound to maintain the confidentiality, and not to make any unauthorized use, of the Proprietary Information in a manner consistent with this Article IX and any
restrictions in the Head License. 
 9.3 Exceptions. The foregoing obligations as to particular Proprietary Information of a Discloser
shall not apply to the extent that the Recipient can demonstrate by competent evidence that such Proprietary Information: 
 (a) is known by
the Recipient at the time of its receipt, and not through a prior disclosure by the Discloser, as shown by contemporaneous written documents of the Recipient; 

(b) is in the public domain by use and/or publication before its receipt from the Discloser, or thereafter enters the public domain through no
fault of, or breach of this Agreement or the Head License by, the Recipient; 
 (c) is subsequently disclosed to the Recipient on a non-confidential basis by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the Discloser; or 

(d) is developed by the Recipient independently and without use of or reference to any Proprietary Information disclosed to it by or on behalf
of the Discloser under this Agreement or the Head License, as shown by contemporaneous written documents of the Recipient. 
 9.4
Authorized Disclosures. Notwithstanding the obligations set forth in Section 9.2, the Recipient may disclose Proprietary Information of the Discloser and the terms of this Agreement to the extent such disclosure both
(i) otherwise permitted under the Head License Agreement and (ii) is reasonably necessary in the following instances: 
 (a) filing
or prosecuting of patents as permitted by and in accordance with this Agreement; 

  
 - 19 - 

 (b) enforcing the Recipient’s rights under this Agreement or performing the
Recipient’s obligations under this Agreement; 
 (c) in Regulatory Filings for Licensed Products that such Party has the right to file
under and in accordance with the terms of this Agreement; 
 (d) prosecuting or defending litigation as permitted by this Agreement; 

(e) to the Recipient’s directors, Affiliates, actual or potential permitted sublicensees, commercial partners, independent contractors,
consultants, attorneys, independent accountants or financial advisors who, in each case, have a need to know such Proprietary Information in order for the Recipient to exercise its rights or fulfill its obligations under this Agreement,
provided, in each case, that any such Person agrees to be bound by terms of confidentiality and non-use (or, in the case of the Recipient’s attorneys and independent accountants, such Person is
obligated by applicable professional or ethical obligations) at least as restrictive as those set forth in this Article IX; 
 (f) to actual
or potential investors, investment bankers, lenders, other financing sources or acquirors (and attorneys and independent accountants thereof) in connection with potential investment, acquisition, collaboration, merger, public offering, due diligence
or similar investigations by such Third Parties or in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by terms of confidentiality and non-use (or,
in the case of the Recipient’s attorneys and independent accountants, such Third Party is obligated by applicable professional or ethical obligations) that are no less stringent than those contained in this Agreement (except to the extent that
a shorter confidentiality period is customary in the industry); and 
 (g) such disclosure is required by court order, judicial or
administrative process or Applicable Law, provided that in such event the Recipient shall promptly inform the Discloser of such required disclosure and provide the Discloser an opportunity to challenge or limit the disclosure obligations.
Proprietary Information that is disclosed as required by court order, judicial or administrative process or Applicable Law shall remain otherwise subject to the confidentiality and non-use provisions of this
IX, and the Recipient shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order, to ensure the continued confidential treatment of such Proprietary Information. 

9.5 Publication. Publications. If either Party wishes to publish or publically disclose the technical or scientific results of any
studies carried out with respect to the Licensed Products or Licensed Compounds in connection with this Agreement, then, it shall provide the other Party with the opportunity to review and comment on any such proposed publication or disclosure which
relates to the Licensed Products or Licensed Compounds at least forty-five (45) days prior to its intended submission for publication or disclosure. The Party proposing publication shall: (a) consider in good faith any comments thereto
provided by the other Party within such forty-five (45) day period; and (ii) remove any Proprietary Information identified by the other Party as part of its review. The Parties acknowledge that any proposed publication or disclosure
contemplated by this Section 9.5 will be submitted by Sublicensor for review and comment by AstraZeneca in accordance with Section 6.5 of the Head License, and any such proposed publication or disclosure

  
 - 20 - 

 
must comply with the rights and obligations of Sublicensor and AstraZeneca under Section 6.5 of the Head License, including, but not limited to, giving due regard to comments furnished by
AstraZeneca and permitting AstraZeneca a reasonable period (not to exceed sixty (60) days) to file for patent protection and to otherwise address issues of Proprietary Information or related competitive harm to AstraZeneca’s reasonable
satisfaction. 
 9.6 Publicity/Use of Names. Except as expressly permitted herein or as required by law, no disclosure of the
existence, or the terms, of this Agreement may be made by either Party or its Affiliates, and neither Party shall use the name, trademark, trade name or logo of AstraZeneca, or its Affiliates, or its and their respective employee(s) in any
publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of AstraZeneca and the other Party. Without limiting the foregoing, each Party and its Affiliates may
disclose on its website, in public announcements and in its promotional materials that the other Party is a (sub)licensee or (sub)licensor of the Licensed Product rights in its applicable field, or that such other Party is a development partner of
such Party in relation to the Licensed Products, and may use the other Party’s name and logo in conjunction with such disclosure; provided that, if following the Effective Date, either Party enters into any agreement assigning or granting a
sublicense to any Third Party of any or all of such Party’s rights under this Agreement or the Head License, then the sublicensing or assigning Party will ensure that such Third Party assignee or sublicensee is obligated not to use the name,
trademark, trade name or logo of AstraZeneca, the other Party, either of respective Affiliates, or any of their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement (or the Head License) or its
subject matter, without the prior express written permission of the other Party. 
 (a) A Party may disclose this Agreement and its terms,
and material developments or material information generated under this Agreement, in securities filings with the U.S. Securities and Exchange Commission (“SEC”) (or equivalent foreign agency) to the extent required by law after
complying with the procedure set forth in this Section 9.6. In such event, the Party seeking to make such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to
request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than three (3) days after receipt of such confidential treatment request and proposed redactions) give its input in a
reasonable manner in order to allow the Party seeking disclosure to file its request within the time lines prescribed by applicable SEC regulations and those timelines needed to comply with the Head License. The Party seeking such disclosure shall
exercise Commercially Reasonable Efforts to obtain confidential treatment of this Agreement from the SEC as represented by the redacted version reviewed by the other Party. The Parties agree to cooperate to ensure that any such filings and any
review of such filings are made in accordance with and pursuant to the terms of the Head License. 
 (b) Further, each Party acknowledges
that the other Party may be legally required, or may be required by the listing rules of any exchange on which the other Party’s or its Affiliate’s securities are traded, to make public disclosures (including in filings with the SEC or
other agency) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by law or such listing rules, provided that the Party seeking such
disclosure shall provide the other Party with a copy of the proposed text of such disclosure sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment thereon, which comments shall be
provided, if at all, within seven (7) Business Days following receipt, or such shorter time as may be required, taking into account the required date of release. 

  
 - 21 - 

 (c) If either Party desires to issue a press release or make a public announcement
concerning the material terms of this Agreement or the Development or Commercialization of the Licensed Product under this Agreement, such as the achievement of Regulatory Approvals of the Licensed Product, such Party shall provide the other Party
with the proposed text of such announcement for prior review and, except to the extent such press release or public announcement is permitted by subsection (a) or (b) above, approval by such other Party and by AstraZeneca pursuant to the terms
of the Head License. The reviewing Party will provide comments, if at all, within seven (7) Business Days following receipt, or such shorter time as may be reasonably requested, taking into account the intended date of release. Subject to the
requirements of the Head License, and Section 1.1 hereof, each Party may make subsequent public disclosures or issue press releases or other public announcements disclosing the same content without having to obtain the
other Party’s prior consent and approval. 
 9.7 Reporting of Financial Information. From and after the Effective Date, to the
extent required by the SEC in connection with registering securities in a public offering, each Party shall cooperate with the other by providing access to information, books, and records related to the Licensed Products as may reasonably request in
connection with the preparation of historical and pro forma financial statements related to the Licensed Products as may be required to be included in any filing made by the other Party or any of its Affiliates under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder, including Regulation S-X and shall use reasonable efforts to exercise any rights under the Head License
enjoyed by such Party to facilitate the same. The requesting Party shall promptly pay or reimburse all documented costs incurred by the providing Party or its Affiliates (or AstraZeneca on behalf of such providing Party) in complying with this
Section 9.7. 
 ARTICLE X 

MISCELLANEOUS 
 10.1
Defined Terms. All terms not otherwise defined in this Agreement shall have the meaning set forth in the Head License. 
 10.2
Notices. All notices that are required or permitted hereunder shall be in writing and shall be sufficient if delivered personally, sent by facsimile, pdf, or electronic mail (that is promptly confirmed personally or by delivery and read
receipts), sent by internationally-recognized courier or sent by registered or certified mail, postage prepaid, addressed as follows: 
 if
to Sublicensee, to: 
 Roivant Sciences GmbH 

Viaduktstrasse 8 
 Basel 4051

 Switzerland 
 Attn: VP,
Head of Global Transactions 

  
 - 22 - 

 With copy to: 

Roivant Sciences, Inc. 
 320
West 37th Street 
 5th Floor 

New York, NY 10018 
 Attn: Legal
Department 
 if to Sublicensor, to: 

Dermavant Sciences GmbH 

Viaduktstrasse 8 
 Basel 4051

 Switzerland 
 Attn: VP,
Head of Global Transactions 
 with copy to: 

Dermavant Sciences, Inc. 
 2398
E. Camelback Rd. 
 Suite #1060 

Phoenix, AZ 85016 
 Attn: Legal
Department 
 10.3 Severability. If any provision of this Agreement is determined to be invalid, illegal or unenforceable, the
remaining provisions of this Agreement remain in full force, if the essential terms and conditions of this Agreement for each party remain valid, binding and enforceable. 

10.4 Entire Agreement. This Agreement constitutes the final agreement between the Parties with respect to the subject matter contained
herein, and is the complete and exclusive statement of the Parties’ agreement on the matters contained herein. All prior and contemporaneous negotiations and agreements between the Parties with respect to the matters contained herein are
superseded by this Agreement. 
 10.5 Amendments. This Agreement may not be amended, modified or changed except by an instrument in
writing signed by both Parties. 
 10.6 Counterparts. The parties may execute this Agreement in multiple counterparts, each of which
constitutes an original as against the Party that signed it, and all of which together constitute one agreement. The signatures of both Parties need not appear on the same counterpart. The delivery of signed counterparts by facsimile, pdf or email
that includes a copy of the sending Party’s signature is as effective as signing and delivering the counterpart in person. 

  
 - 23 - 

 10.7 Successors and Assigns. Except as provided in this Section 10.7,
this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party, without the written consent of the other Party; provided that Sublicensor may, without the
other Party’s consent, assign or otherwise transfer this Agreement and all of its rights and obligations hereunder to the assignee or transferee of all of its rights and obligations under the Head License, including, without limitation, to any
successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement relates. Any attempted assignment not in accordance with this
Section 10.7 shall be void. The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respective successors and permitted assigns. 

10.8 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in performing any obligation under this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party including, but not limited to, embargoes, war, acts
of war (whether war has been declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the
other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. 

10.9 Interpretation. In this Agreement, unless otherwise specified: 

(a) “includes” and “including” shall mean respectively includes and including without limitation; 

(b) words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders; and 

(c) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the
particular provision in which such words appear. 
 [Remainder of page intentionally left blank] 

  
 24 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement to be effective
as of the Effective Date. 
  

							
	DERMAVANT SCIENCES GMBH	 	ROIVANT SCIENCES GMBH
				
	By:	 	 /s/ Ruben Masar
	 	By:	 	 /s/ Sascha Bucher

	Name:	 	Ruben Masar	 	Name:	 	Sascha Bucher
	Title:	 	Secretary of the Board	 	Title:	 	Roivant Sciences GmbH
		 		 		 	Sascha Bucher
		 		 		 	VP, Head of Global Transactions

 [Signature Page to Sublicense Agreement for RVT-503] 

 Annex A 

Head License 

[See attached]EX-10.10

 Exhibit 10.10 

CONFIDENTIAL 
 Execution Copy 

ASSIGNMENT AND ASSUMPTION AGREEMENT 

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment and Assumption Agreement”) is made and entered into as of
December 17, 2018 (the “Effective Date”), by and between Dermavant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051,
Switzerland (“DSG”) and Roivant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051, Switzerland (“RSG”). 

A. WHEREAS, RSG entered into a License Agreement with TheraVida, Inc., a corporation organized and existing pursuant to the laws of Delaware
having a principal place of business at 177 Bovet Rd., Suite 600, San Mateo, California 94402 (“TheraVida”) effective as of January 31, 2018 (the “TheraVida Agreement”), pursuant to which RSG received an
exclusive license from TheraVida to research, develop, manufacture and commercialize certain products for the treatment, prevention and diagnosis of any and all human and animal diseases disorders and conductions with the exception of overactive
bladder; 
 B. WHEREAS, RSG and Roivant China Holdings Ltd. (formerly known as Sinovant Sciences Ltd., a Bermuda exempted limited company)
(“SSL”), entered into that certain China and South Korea IP Purchase Agreement, dated February 14, 2018 (the “Sinovant Agreement”), pursuant to which RSG assigned all of its rights under the TheraVida Agreement
to SSL relating to China, Hong Kong, Macau and Taiwan (“Greater China”), as more specifically set forth therein. 
 C.
WHEREAS, SSL and its subsidiary, Sinovant Sciences HK Limited (“SinoHK”), entered that certain Intellectual Property License Agreement, dated March 16, 2018, pursuant to which SSL sublicensed to SinoHK, inter alia, its
intellectual property rights under the Sinovant Agreement in Greater China; 
 D. WHEREAS, RSG desires to assign and transfer to DSG all of
RSG’s rights and obligation under the TheraVida Agreement, as set forth below (which, for clarity, excludes the rights transferred to SSL pursuant to the Sinovant Agreement), and DSG desires to accept such assignment and transfer. 

NOW, THEREFORE, for good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the parties
hereto hereby agree as follows: 
 1. Defined Terms. Capitalized terms used but not otherwise defined in this Assignment and
Assumption Agreement shall have the meanings given to such terms in the TheraVida Agreement. 
 2. Assignment;
Reversion. 
 (a) Initial Assignment. RSG hereby grants, conveys, transfers and assigns to DSG and its successors
and assigns, all of the rights, title and interests of RSG in and to (a) the TheraVida Agreement, excluding as it relates to any rights, title or interests that have, as of the 

  
 - 1 - 

 Effective Date, been assigned, licensed, sublicensed by or on behalf of RSG to any Affiliate of RSG or any
Third Party, whether directly or indirectly, to develop and commercialize any Licensed Product in Greater China, (b) any and all Roivant Technology and Inventions and all other intellectual property rights of RSG under the TheraVida Agreement,
excluding any intellectual property rights that have, as of the Effective Date, been assigned, licensed, sublicensed by or on behalf of RSG to any Affiliate of RSG or any Third Party, whether directly or indirectly, to develop and commercialize any
Licensed Product in Greater China and (c) any and all Regulatory Filings and Regulatory Approvals for Proprietary Drugs and Licensed Products in the Field in the Territory, excluding any Regulatory Filings and Regulatory Approvals that have, as
of the Effective Date, been assigned, licensed, sublicensed by or on behalf of RSG to any Affiliate or Third Party, whether directly or indirectly, to develop and commercialize any Licensed Product in Greater China (collectively, the
“Assigned Assets”). 
 (b) Reversion; Additional Assignments to DSG. Without limiting Section 2(a), if RSG has
granted to an Affiliate of RSG or any Third Party some or all of its rights in any country(ies) or administrative jurisdiction(s) in Greater China under the TheraVida Agreement as of the Effective Date, and the agreement with such Affiliate or such
Third Party is modified or terminated following the Effective Date in a manner that causes a reversion of such rights under the TheraVida Agreement in such country(ies) or administrative jurisdiction(s) to RSG, then, RSG may exploit such rights in
any such reverted country(ies) or administrative jurisdiction(s) on behalf of itself or may grant, transfer or otherwise convey such rights to an Affiliate of RSG, in either case, without further obligation to DSG hereunder. Notwithstanding the
foregoing, upon any such reversion of rights to RSG, unless otherwise agreed in writing, RSG shall not grant, transfer or otherwise convey any of the reverted rights under the TheraVida Agreement for the exploitation of Licensed Products or
Proprietary Drugs in Greater China to any Third Party. If RSG elects not to exploit such reverted rights under the TheraVida Agreement itself or through a grant, transfer or conveyance of rights to an Affiliate of RSG, then RSG shall and hereby does
grant, convey, transfer and assign to DSG and its successors and assigns, all of the rights, title and interests of RSG in and to (i) the TheraVida Agreement, (ii) Roivant Technology and Inventions and (iii) any Regulatory Filings and
Regulatory Approvals for Proprietary Drugs and Licensed Products in such reverted country or administrative jurisdiction in Greater China, in each case of (i)-(iii) to the extent reasonably possible without violating applicable law or any
contractual agreement with any Third Party. Following such assignment, the ‘Assigned Assets’ shall automatically include those assets described in the foregoing sentence (i)-(iii), which, unless otherwise agreed will automatically be
sublicensed by DSG back to RSG for use outside of dermatology and overactive bladder pursuant to that certain Sublicense Agreement by and between DSG and RSG, dated as of the date hereof (the “Sublicense Agreement”). RSG shall
promptly notify DSG of any termination of modification of any agreement with any Affiliate or Third Party involving the rights under the TheraVida Agreement in some or all of Greater China and the Parties shall, on DSG’s request, meet in good
faith to discuss such additional assignment of rights and any appropriate agreements or amendments to existing agreements required in connection with the same. 

3. Assumption of Liabilities. DSG does hereby assume and agree to pay, perform, honor and discharge, as and when due, any obligations
and liabilities that may arise under the TheraVida Agreement from the date hereof to the extent transferred to DSG under Section 2 above (the “Assumed Liabilities”). 

  
 - 2 - 

 4. Consideration; Payment. Concurrently with the execution of this Assignment and
Assumption Agreement, DSG shall pay to RSG (to an account specified by RSG) an amount equal to two million U.S. dollars ($2,000,000), as consideration for the fair market value, as determined by an independent third party, of the assignment of the
Assigned Assets and assumption of the Assumed Liabilities. 
 5. Indemnification. Subject to RSG’s obligation to indemnify DSG
pursuant to Section 6.2(a) of the Sublicense Agreement, DSG shall indemnify, defend and hold RSG harmless from and against all liabilities, damages, expenses, losses, including reasonable legal expenses and attorneys’ fees, and any other
expenses of any nature, resulting from (a) DSG’s exercise of rights and performance or non-performance of its duties or obligations under the TheraVida Agreement to the extent assumed under this
Agreement and/or (b) any other TheraVida demand, claim, action, proceeding or liability after the date hereof (whether criminal or civil, in contract, tort or otherwise) against RSG arising or resulting from, or initiated under, the TheraVida
Agreement (whether in reliance on the proviso in clause (b) of the first sentence of Section 14.2 of the TheraVida Agreement or otherwise), except to the extent related to (i) any rights or obligations under the TheraVida Agreement
that are sublicensed by DSG back to RSG pursuant to the Sublicense Agreement or (ii) Greater China or any of the rights or obligations under the TheraVida Agreement that were transferred pursuant to the Sinovant Agreement. 

6. Reversion Right. In the event that (a) DSG ceases all Development of Proprietary Drugs and Licensed Products in the Field in the
Territory (or the funding thereof) with no plans to resume such Development (it being understood that the level of effort directed to such Development may change over time and may include reasonable periods where Development is temporarily de-prioritized or otherwise temporarily suspended), or (b) DSG notifies RSG in writing of its intention to proceed in the manner set forth in clause (a), then, RSG may elect to have all or part of the rights,
title and interests granted to DSG pursuant to Section 2 of this Assignment and Assumption Agreement, together with any or all of the Roivant Technology, Inventions, Regulatory Filings and Regulatory Approvals, Third Party Licenses, and
agreements with subcontractors for, and any or all other property or assets primarily relating to, the Proprietary Drugs and Licensed Products in the Field in the Territory that DSG Controls as of such time, assigned to RSG and its successors and
assigns and DSG shall complete such assignment within thirty (30) days of DSG’s receipt of written notice of such election from RSG. Concurrently with the assignment, RSG shall pay DSG (to an account specified by DSG) an amount intended to
account for the fair market value of the transfer of such rights, as determined by an independent third party. If RSG elects to obtain such assignments, and solely to the extent permissible under the TheraVida Agreement, on DSG’s request, RSG
and DSG shall work in good faith to ensure that DSG is provided with the benefit of any of the property and assets assigned to RSG under this Section 6 (whether through non-exclusive licenses or
otherwise) to the extent necessary or reasonably useful for the research, development and commercialization of DSG’s or its Affiliates’ products (other than the Licensed Products or the Proprietary Drugs). To the extent that RSG elects not
to have assigned any of the foregoing items, DSG shall terminate, cancel, wind-down or otherwise cease to support such retained items after assignment, unless the retention of such property or assets is (i) not prohibited or inconsistent with
the TheraVida Agreement, and (ii) necessary or reasonably useful for the research, development and commercialization of DSG’s or 

  
 - 3 - 

 its Affiliates’ products (other than the Licensed Products or the Proprietary Drugs). For the avoidance
of doubt, the indemnification obligations set forth in Section 5 of this Assignment and Assumption Agreement shall continue in full force and effect in respect of all indemnifiable losses that arose prior to such assignment. 

7. Successors and Assigns. This Assignment and Assumption Agreement shall bind and inure to the benefit of the respective successors and
assigns of DSG and RSG. 
 8. Governing Law. This Assignment and Assumption Agreement shall be governed by and construed in accordance
with the laws of the State of New York, without regard to conflict of laws principles. 
 9. No Third Party Rights. Nothing express or
implied in this Assignment and Assumption Agreement is intended or shall be construed to confer on any person other than DSG and RSG any rights under this Assignment and Assumption Agreement. 

10. Further Assurances. Each party hereto, upon the request of the other party hereto, whether before or after the Effective Date and
without further consideration, will do, execute, acknowledge, and deliver or cause to be done, executed, acknowledged or delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers of attorney, instruments and
assurances as may be reasonably necessary to effect complete consummation of the transactions contemplated by this Assignment and Assumption Agreement, and to do all such other acts, as may be necessary or appropriate in order to carry out the
purposes and intent of this Assignment and Assumption Agreement. The parties hereto agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order
to consummate or implement expeditiously the transactions contemplated by this Assignment and Assumption Agreement. 
 11. Costs and
Expenses. Each of the parties hereto shall pay its own costs and expenses incurred or to be incurred in negotiating, closing and executing all transactions contemplated by this Assignment and Assumption Agreement. 

12. Counterparts. This Assignment and Assumption Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be deemed an original, and such counterparts together shall constitute one instrument. 
 13. Amendments and
Waivers. The provisions of this Assignment and Assumption Agreement may be amended or waived only by an instrument in writing signed by DSG and RSG. Any waiver of any term or condition of this Assignment and Assumption Agreement or any breach
hereof shall not operate as a waiver of any other such term, condition or breach, and no failure to enforce any provision hereof shall operate as a waiver of such provision or of any other provision hereof. 

14. Headings. The headings are for convenience only and will not control or affect the meaning or construction of the provisions of this
Assignment and Assumption Agreement. 
 [Signature Page Follows.] 

  
 - 4 - 

 IN WITNESS WHEREOF, the undersigned have caused this Assignment and Assumption Agreement to
be duly executed and delivered as of the date first above written. 
  

			
	ROIVANT SCIENCES GMBH
		
	By:	 	 /s/ Sascha Bucher

	Name:	 	Sascha Bucher
	Its:	 	 Roivant Sciences GmbH
 Sascha Bucher

VP, Head of Global Transactions

	
	DERMAVANT SCIENCES GMBH
		
	By:	 	 /s/ Ruben Masar

	Name:	 	Ruben Masar
	Its:	 	Secretary of the Board

 [Signature Page to Assignment and Assumption Agreement for
RVT-504]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]